JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Order Through VWR & Receive a FREE Sample

Support: [email protected]

Track Your Order

Home
Bioactive Compounds

Bioactive Compounds

B8772 CFT8634

Summary: An orally active BRD9-targeting degrader for research on tumors such as synovial sarcoma.

≥44 mg/mL
A3016 PLX-4720
1 Citation

Target: Raf

Summary: BRAF kinase inhibitor

≥20.69 mg/mL
A3017 Dasatinib (BMS-354825)
14 Citation

Summary: Src and Bcr-Abl inhibitor

≥24.4 mg/mL
A4003 LDN 57444

Target: UCH

Summary: UCH-L1 inhibitor,reversible competitve

insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL
A2576 E-64
6 Citation

Target: Cathepsins|Calpains|Papains

Summary: cysteine proteases inhibitor

≥49.1 mg/mL
A2603 Calpain Inhibitor II, ALLM
5 Citation

Summary: Calpain inhibitor

insoluble in H2O; ≥14.85 mg/mL
A2578 Clasto-Lactacystin β-lactone

Target: Proteasome

Summary: Proteasome inhibitor

Soluble in DMSO
A4018 YO-01027 (Dibenzazepine, DBZ)
1 Citation

Summary: γ-secretase inhibitor

≥23.17 mg/mL
A4056 AT13387

Target: HSP90

Summary: Hsp90 inhibitor

insoluble in H2O; ≥13.25 mg/mL
A4182 Resveratrol
7 Citation

Target: Sir2-like Family Deacetylases (Sirtuins)|COX|LOX|Adenylyl cyclase|Quinone reductase

Summary: SIRT1 activator